CellCentric Secures £90 Million to Boost Innovative Oral Therapy for Multiple Myeloma
Cambridge, England — CellCentric, a MedTech firm focused on cancer treatments, has successfully secured £90 million in its latest funding round. This capital injection will expedite the development of inobrodib, an innovative oral therapy aimed at treating multiple myeloma, a form of blood cancer. The Series C funding round was co-led by RA Capital Management … Read more